Evidence map›Paper›PMID 35736245›Full record

ArticleEuropean journal of histochemistry : EJH2022

Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma.

Kazuhiko Hashimoto, Shunji Nishimura, Tomohiko Ito, Naohiro Oka, Ryosuke Kakinoki, Masao Akagi

Open access · goldAbstract read
In one paragraph

Article in European journal of histochemistry : EJH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Clinicopathological correlations and prognostic insights in osteosarcoma: a retrospective analysis.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kazuhiko HashimotoDepartment of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. hazzhiko@med.kindai.ac.jp.
Shunji NishimuraDepartment of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. shunnisi@med.kindai.ac.jp.
Tomohiko ItoDepartment of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. tomo0251118zooo@gmail.com.
Naohiro OkaDepartment of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. n-oka@med.kindai.ac.jp.
Ryosuke KakinokiDepartment of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. rkakinoki@med.kindai.ac.jp.
Masao AkagiDepartment of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. makagi@med.kindai.ac.jp.
Kindai University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cancer/testis antigens (CTAs), New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and melanoma antigen gene (MAGE)-A4 are normally restricted to male germ cells but are aberrantly expressed in several cancers. Considering the limited information regarding their significance in osteosarcoma (OS), the purpose of this study was to determine the clinical significance of NY-ESO-1 and MAGE-A4 expression in OS. Nine patients with OS treated at Kindai University Hospital were included in the study. The median age was 27 years, and median follow-up period was 40 months. The specimens obtained at the time of biopsy were used to perform immunostaining for NY-ESO, MAGE-A4, p53, and Ki-67. The positive cell rates and positive case rates of NY-ESO, MAGE-A4, p53, and Ki-67 were calculated. The correlation between the positive cell rate of immunohistochemical markers was also calculated. The correlation between the positive cell rate of NY-ESO-1 or MAGE-A4 and tumor size or maximum standardized uptake (SUV-max) was also determined. The positive cell rates of NY-ESO-1 or MAGE-A4 in continuous disease-free (CDF) cases were also compared with those in alive with disease (AWD) or dead of disease (DOD) cases. The average positive cell rates of NY-ESO, MAGEA4, p53, and Ki-67 were 71.7%, 85.1%, 16.2%, and 14.7%, and their positive case rates were 33.3%, 100%, 44.4%, and 100%, respectively. The positivity rates of NY-ESO-1 and p53 were strongly correlated, whereas those of NY-ESO-1 and Ki-67 were moderately correlated. The MAGE-A4 and p53 positivity rates and the MAGE-A4 and Ki-67 positive cell rates were both strongly correlated. The NY-ESO-1 and MAGE-A4 positivity rates were moderately correlated. The positive correlation between the NY-ESO-1 positive cell rate and tumor size was medium, and that between the MAGE-A4 positivity rate and SUV-max was very strong. There was no significant difference in the positive cell rates of NY-ESO-1 or MAGE-A4 between CDF cases and AWD or DOD cases. Overall, our results suggest that NY-ESO-1 and MAGE-A4 may be involved in the aggressiveness of OS.

Indexed as

Antigens, NeoplasmBone NeoplasmsMembrane ProteinsNeoplasm ProteinsOsteosarcomaAdultBiomarkers, TumorHumansKi-67 AntigenMalePrognosisTumor Suppressor Protein p53Antigens, NeoplasmBiomarkers, TumorCTAG1B protein, humanKi-67 AntigenMAGEA4 protein, humanMembrane ProteinsNeoplasm ProteinsTumor Suppressor Protein p53

Identifiers

PMID35736245
PMCPMC9251608
OpenAlexW4283320825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.